Home / business / Aurobindo Pharma Shares Climb 19% after USFDA Issues EIR for Unit IV

Aurobindo Pharma Shares Climb 19% after USFDA Issues EIR for Unit IV

-
EIR is basically a factual report on all the activities conducted by FDA investigators during the time spent at the manufacturing establishment.

from Top Business News- News18.com
Read The Rest:timesnownews...
Aurobindo Pharma Shares Climb 19% after USFDA Issues EIR for Unit IV Aurobindo Pharma Shares Climb 19% after USFDA Issues EIR for Unit IV Reviewed by Team Exprssnews on February 18, 2020 Rating: 5

No comments:

Subscribe to: Post Comments ( Atom )
Powered by Blogger.